Ramky Infra Secures ₹3,000 Crore High-Tech Pharma Park Project in Maharashtra
Ramky Infrastructure's subsidiary, MILeS City, has secured a 95-year concession from MIDC to develop a High-Tech Pharmaceutical Park in Maharashtra. The project, with an estimated cost of ₹3,000 Crores, includes development, operation, and maintenance over 1000 hectares.
The project is of substantial value (₹3,000 Crores) and has a long concession period (95 years), which will significantly contribute to the company's future revenue and market position.
The company has been awarded a significant new project with a substantial value, indicating business growth and expansion.
Ramky Infrastructure Limited (Ramky Infra) has been awarded a significant project by the Maharashtra Industrial Development Corporation (MIDC) through its wholly-owned subsidiary, Maha Integrated Life Sciences City Limited (MILeS City). This concession agreement is for the "Development, Operation, Maintenance and Management of the upcoming High-Tech Pharmaceutical Park in Dighi Port Industrial Area Mangaon & Roha Taluk, Raighad District in the state of Maharashtra on PPP Basis".
The project involves the development of an industrial park spanning 1000 hectares in Raigad District, Maharashtra. It will include an Industrial Zone, Commercial Zone, Common Amenities, Utilities, and Roads. The concession period is set for 95 years, including a construction period of 5 years. This initiative aims to provide a comprehensive solution for the Life Sciences and Pharma sectors, offering sustainable infrastructure for establishing their units.
The total estimated project cost is ₹3,000 Crores. Ramky Infra will generate revenue through Land Lease Premium, Development Charges, Maintenance income for services, and Operation income from utilities. This project is expected to position Ramky Infra as a key player in providing specialized infrastructure for the Life Sciences and Pharma sectors.
What to do with a filing like this
Ramky Infrastructure Limited filed this with the NSE as a statutory disclosure, categorised under new orders. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Ramky Infrastructure Limited. Read the original for the full detail.